Alpha 2.0
Login Register
» Authors » Shuichi Shirane

Shuichi Shirane

Explore the profile of Shuichi Shirane including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 42
Citations 291
Followers 0
Related Specialties
Hematology
Infectious Diseases
Oncology
Top 10 Co-Authors
Norio Komatsu
Yoko Edahiro
Soji Morishita
Miki Ando
Marito Araki
Tadaaki Inano
Hajime Yasuda
Yasuharu Hamano
Tomonori Ochiai
Chiho Furuya
Published In
Int J Hematol
Rinsho Ketsueki
Hematology
Br J Haematol
Ann Hematol
Affiliations
Soon will be listed here.
Recent Articles
11.
gene mutation is a possible risk factor for thrombosis in patients with essential thrombocythemia in Japan
Furuya C, Hashimoto Y, Morishita S, Inano T, Ochiai T, Shirane S, et al.
Hematology . 2023 Jun; 28(1):2229131. PMID: 37378567
Objectives: Since mutation is a rare driver gene mutation found in a small number of essential thrombocythemia (ET) patients, the clinical characteristics of patients with mutations and their association with...
12.
Clinical characteristics of Japanese patients with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis
Edahiro Y, Ochiai T, Hashimoto Y, Morishita S, Shirane S, Inano T, et al.
Int J Hematol . 2023 Apr; 118(1):47-53. PMID: 37058247
Myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T) is a rare disease, which presents with features of myelodysplastic syndromes with ring sideroblasts and essential thrombocythemia, as well as anemia and...
13.
Reevaluation of cardiovascular risk factors for thrombotic events in 580 Japanese patients with essential thrombocythemia
Furuya C, Hashimoto Y, Morishita S, Inano T, Ochiai T, Shirane S, et al.
J Thromb Thrombolysis . 2022 Dec; 55(2):263-272. PMID: 36484956
Risk-adapted therapy is recommended to prevent thrombosis in essential thrombocythemia (ET) patients. An advanced age, a history of thrombosis, and the presence of the JAK2V617F mutation are well-defined risk factors...
14.
Non-driver gene mutation analysis in a large cohort of polycythemia vera and essential thrombocythemia
Morishita S, Hashimoto Y, Furuya C, Edahiro Y, Ochiai T, Shirane S, et al.
Eur J Haematol . 2022 Oct; 110(2):131-136. PMID: 36208190
Objectives: A proportion of patients with polycythemia vera (PV) and essential thrombocythemia (ET) harbor non-driver mutations associated with poor prognosis. In this study, we analyzed the frequency of non-driver mutations...
15.
Central nervous system mucormycosis in a patient with hematological malignancy: A case report and review of the literature
Shirane S, Najima Y, Fukushima K, Sekiya N, Funata N, Kishida Y, et al.
J Infect Chemother . 2022 Aug; 28(12):1658-1662. PMID: 35963603
Invasive mucormycosis is a refractory fungal infection. Central nervous system (CNS) mucormycosis is a rare complication caused by infiltration from the paranasal sinuses or hematogenous dissemination. Here, we present a...
16.
Clinical features of acquired erythrocytosis: Low levels of serum erythropoietin in a subset of non-neoplastic erythrocytosis patients
Mori Y, Araki M, Morishita S, Imai M, Edahiro Y, Ito M, et al.
Cancer Med . 2022 Jul; 12(2):1079-1089. PMID: 35775283
Background: Acquired erythrocytosis can be classified into polycythemia vera (PV) and non-neoplastic erythrocytosis (NNE). The vast majority of PV patients harbor JAK2 mutations, but differentiating JAK2 mutation-negative PV from NNE...
17.
Vitamin B6 deficiency as a cause of polyneuropathy in POEMS syndrome: rapid recovery with supplementation in two cases
Yasuda H, Furukawa Y, Nishioka K, Sasaki M, Tsukune Y, Shirane S, et al.
Hematology . 2022 Apr; 27(1):463-468. PMID: 35413228
Background: The etiology of POEMS syndrome and its associated polyneuropathy have not been fully elucidated. The clinical picture of POEMS-associated polyneuropathy and nutritional polyneuropathy due to vitamin B6 (VB6) deficiency...
18.
[Systemic chemotherapy combined with thrombopoietin receptor agonist for the treatment of diffuse large B-cell lymphoma complicated with aplastic anemia]
Fukuda Y, Edahiro Y, Takaku T, Furuya C, Shirane S, Hamano Y, et al.
Rinsho Ketsueki . 2022 Feb; 63(1):20-25. PMID: 35135947
Immunosuppressive therapies, including antithymocyte globulin and cyclosporine (CsA), are used for the treatment of aplastic anemia, but they reportedly cause lymphoproliferative diseases. Here, we report two cases of aplastic anemia...
19.
Validation and reliability of current guidelines for the treatment of essential thrombocythemia under real-world clinical settings in Japan
Baba T, Hashimoto Y, Yasuda H, Araki M, Edahiro Y, Morishita S, et al.
Hematology . 2022 Jan; 27(1):157-166. PMID: 35068369
Objective: Current guidelines for essential thrombocythemia (ET) patients recommend different treatment approaches based on thrombosis risk stratification models. However, these recommendations may not be applicable to some patients under real...
20.
Advances in Allogeneic Cancer Cell Therapy and Future Perspectives on "Off-the-Shelf" T Cell Therapy Using iPSC Technology and Gene Editing
Furukawa Y, Hamano Y, Shirane S, Kinoshita S, Azusawa Y, Ando J, et al.
Cells . 2022 Jan; 11(2). PMID: 35053386
The concept of allogeneic cell therapy was first presented over 60 years ago with hematopoietic stem cell transplantation. However, complications such as graft versus host disease (GVHD) and regimen-related toxicities...